Overall, tumor heterogeneity at the time of acquired resistance to anti-EGFR treatment represents a significant obstacle to the development of precision medicine strategies, and suggests the potential usefulness of large-scale cfDNA profiling to define the genomic landscape of tumor heterogeneity and therapeutic resistance. The gene discussed is EGFR; the disease is neoplasm.